A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2223-2232

  Frigerio, B ^a   Fracasso, G ^b   Luison, E ^a   Cingarlini, S ^c   Mortarino, M ^a   Coliva, A ^a   Seregni, E ^a   Bombardieri, E ^a   Zuccolotto, G ^d   Rosato, A ^d,e   Colombatti, M ^b   Canevari, S ^a   Figini, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Imaging; Prostate cancer; Prostate specific membrane antigen; Single chain Fv

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STABILITY; PROTEIN TARGETING; RADIOCHEMISTRY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, SURFACE; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; ENZYME STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTAMATE CARBOXYPEPTIDASE II; HETEROGRAFTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; MALE; MICE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RADIOIMMUNOASSAY; SINGLE-CHAIN ANTIBODIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84877711673     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.024     Document Type: Article

References (35)

1. R.S. Israeli, C.T. Powell, J.G. Corr, W.R. Fair, and W.D. Heston Expression of the prostate-specific membrane antigen Cancer Res 54 1994 1807 1811
2. G.L. Wright, C. Haley, M.L. Beckett, and P.F. Schellhammer Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissue Urol Oncol 1 1995 18 28
3. G.L. Wright Jr., B.M. Grob, and C. Haley Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326 334
4. S.D. Sweat, A. Pacelli, G.P. Murphy, and D.G. Bostwick Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 1998 637 640
5. K. Bouchelouche, P.L. Choyke, and J. Capala Prostate specific membrane antigen-a target for imaging and therapy with radionuclides Discov Med 9 2010 Jan 55 61
6. A.L. Nelson, E. Dhimolea, and J.M. Reichert Development trends for human monoclonal antibody therapeutics Nat Rev Drug Discov 9 2010 767 774
7. P.J. Carter Potent antibody therapeutics by design Nat Rev Immunol 6 2006 343 357
8. A. Ghosh, X. Wang, E. Klein, and W.D. Heston Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness Cancer Res 65 2005 727 731
9. R.D. Jachimowicz, G. Fracasso, and P.J. Yazaki Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma Mol Cancer Ther 10 2011 1036 1045
10. J. Vellinga, V.J. de, and S. Myhre Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid Gene Ther 14 2007 664 670
11. H. Liu, P. Moy, and S. Kim Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res 57 1997 3629 3634
12. H.R. Hoogenboom, A.D. Griffiths, and K.S. Johnson Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains Nucleic Acids Res 19 1991 4133 4137
13. M. Figini, L. Obici, and D. Mezzanzanica Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection Cancer Res 58 1998 991 996
14. S.E. Burastero, B. Frigerio, and L. Lopalco Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4 PLoS One 6 2011 e22081
15. R. Robert, A.M. Noubhani, M.J. Jacobin, X. Santarelli, and G. Clofent-Sanchez Improvement in production and purification bioprocesses of bacterially expressed anti-alphaIIbbeta3 human single-chain FV antibodies J Chromatogr B Analyt Technol Biomed Life Sci 818 2005 43 51
16. 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas Cancer Immunol Immunother 54 2005 1200 1213
17. M. Figini, F. Martin, and R. Ferri Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor Cancer Immunol Immunother 58 2009 531 546
18. A. Zacchetti, A. Coliva, and E. Luison (177)Lu-labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts Nucl Med Biol 36 2009 759 770
19. S. Bobisse, M. Rondina, and A. Merlo Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors Cancer Res 69 2009 9385 9394
20. Martin ACR. Protein sequence an structure analysis of antibody variable domains. In: Kontermann R, Dubel S, editors. Antibody engineering. 2001 ed. 2001. p. 422-439.
21. W.C. Olson, W.D. Heston, and A.K. Rajasekaran Clinical trials of cancer therapies targeting prostate-specific membrane antigen Rev Recent Clin Trials 2 2007 182 190
22. H. Shim One target, different effects: a comparison of distinct therapeutic antibodies against the same targets Exp Mol Med 43 2011 539 549
23. R.K. Jain, and L.T. Baxter Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure Cancer Res 48 1988 7022 7032
24. T. Yokota, D.E. Milenic, M. Whitlow, and J. Schlom Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 52 1992 3402 3408
25. 123I or 99mTc Cancer Res 50 1990 909s 921s
26. L.S. Cheng, A.P. Liu, and J.H. Yang Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2) Cell Res 13 2003 35 48
27. K.M. Arndt, K.M. Muller, and A. Pluckthun Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment Biochemistry 37 1998 12918 12926
28. D. Rothlisberger, A. Honegger, and A. Pluckthun Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability J Mol Biol 347 2005 773 789
29. P.M. Smith-Jones, S. Vallabahajosula, and S.J. Goldsmith In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen Cancer Res 60 2000 5237 5243
30. 213Bi]J591) for radioimmunotherapy of prostate cancer Cancer Res 60 2000 6095 6100
31. G. Fracasso, G. Bellisola, and S. Cingarlini Anti-tumor effects of toxins targeted to the prostate specific membrane antigen Prostate 53 2002 9 23
32. N.H. Akhtar, O. Pail, A. Saran, L. Tyrell, and S.T. Tagawa Prostate-specific membrane antigen-based therapeutics Adv Urol 2012 2012 973820
33. J.V. Leyton, T. Olafsen, and E.J. Lepin Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Clin Cancer Res 14 2008 7488 7496
34. E.J. Lepin, J.V. Leyton, and Y. Zhou An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors Eur J Nucl Med Mol Imaging 37 2010 1529 1538
35. A.C. Chan, and P.J. Carter Therapeutic antibodies for autoimmunity and inflammation Nat Rev Immunol 10 2010 301 316